Diabetes Newly Diagnosed And Monitoring Panel
This diabetes monitoring panel bundles A1c, glucose, insulin, kidney, liver, lipid, and inflammation markers to track control and treatment response.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
This is a lab panel, meaning you get multiple related tests from one blood draw (and, for some versions, a urine sample). It is designed for the first months after a diabetes or prediabetes diagnosis and for ongoing monitoring—especially if you are adjusting lifestyle, starting or changing medications (including GLP-1 therapy), or trying to reconcile day-to-day glucose readings with your A1c.
Instead of focusing on one number, this panel helps you connect the dots between average glucose exposure (A1c), current glucose and insulin patterns, cardiometabolic risk (lipids and inflammation), and organ “safety checks” that matter when glucose has been elevated (kidney and liver markers).
Do I need this panel?
You may want this panel if you were newly diagnosed with type 2 diabetes or prediabetes and you want a clearer baseline than a single A1c result can provide. Many people feel stuck when their home glucose readings look “better” than their A1c suggests, or when weight changes and medication changes do not seem to match what their labs are showing.
This panel is also useful if you are monitoring treatment response. That includes lifestyle changes, metformin, GLP-1/GIP or GLP-1 medications, SGLT2 inhibitors, insulin, or combination therapy. The goal is not just to see whether glucose is lower, but whether your overall risk picture is improving and whether your kidneys and liver are tolerating the plan.
You may especially benefit if you have any of these situations: a recent medication start or dose change, a weight-loss plateau, concerns about muscle loss while dieting, symptoms that could relate to high or low glucose (fatigue, thirst, frequent urination, blurry vision), or a family history of early heart disease.
This panel supports clinician-directed care by giving you a structured set of measurements to discuss with your healthcare team. It is not meant to diagnose on your own or replace medical evaluation when you have symptoms or very high readings.
Methods and reference ranges vary by lab; your results should be interpreted using the ranges shown on your report and in the context of your medications, recent illness, and timing of your last meal.
Lab testing
Order the Diabetes Newly Diagnosed And Monitoring Panel
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault makes it straightforward to order a multi-marker diabetes monitoring panel and get a single, organized report you can use for next-step decisions. You can use it to establish a baseline after diagnosis, check progress after a change in therapy, or trend results over time.
Because this is a panel, you are not relying on one lab value to tell the story. You can compare A1c with fasting glucose, look at insulin alongside glucose to understand insulin resistance, and track lipids and inflammation that influence long-term cardiovascular risk.
If you want help making sense of patterns across multiple results—especially when you are on GLP-1 therapy or adjusting medications—PocketMD can help you turn the panel into practical questions to bring to your clinician and a plan for what to recheck next.
- Designed for trending: repeat the same panel to see direction, not just a single snapshot
- Multi-system view: glucose control plus kidney, liver, and lipid monitoring in one order
- Clear next steps: use PocketMD to connect results with questions for your clinician
Key benefits of the Diabetes Newly Diagnosed And Monitoring Panel
- Gives you a baseline across glucose, insulin, lipids, kidney, and liver markers after a new diagnosis.
- Helps explain an A1c-versus-glucose mismatch by pairing average exposure (A1c) with fasting values.
- Tracks insulin resistance patterns that can guide lifestyle focus and medication conversations.
- Monitors kidney and urine albumin markers that matter early in diabetes, even when you feel fine.
- Adds cardiometabolic risk context (lipids and inflammation) so progress is not judged by glucose alone.
- Supports medication monitoring, including GLP-1 therapy, by checking safety-related labs alongside outcomes.
- Makes retesting more consistent by bundling key markers into one repeatable lab panel.
What is the Diabetes Newly Diagnosed And Monitoring Panel?
The Diabetes Newly Diagnosed And Monitoring Panel is a bundled set of lab tests that look at diabetes from several angles at the same time. It typically includes markers of:
• Glycemic control over time (hemoglobin A1c) • Current glucose and insulin physiology (fasting glucose and fasting insulin, often with an insulin-resistance estimate) • Cardiometabolic risk (cholesterol and triglycerides, sometimes with an inflammation marker) • Organ health that can be affected by diabetes or by medications (kidney function, urine albumin, and liver enzymes)
A single marker can be misleading. For example, A1c reflects average glucose exposure over roughly 2–3 months, but it can be influenced by red blood cell turnover, anemia, and other factors. Fasting glucose can look “fine” on a good day while A1c remains elevated, or fasting glucose can be high while A1c is near target if spikes are not frequent. Looking at multiple markers together helps you see whether the pattern fits insulin resistance, medication timing, dietary changes, or a measurement issue.
This panel is commonly used at diagnosis, after major changes (starting GLP-1 therapy, adding an SGLT2 inhibitor, changing insulin strategy), and for periodic monitoring to reduce long-term risk—especially cardiovascular and kidney risk.
What do my panel results mean?
When results trend low
In a diabetes monitoring panel, “low” usually matters most for glucose-related values that could signal hypoglycemia risk (for example, low fasting glucose), or for markers that can drop due to nutrition changes during weight loss (such as low triglycerides alongside very low calorie intake). If your fasting glucose is low while A1c is also low or rapidly falling, it can fit with medication effects (insulin or insulin secretagogues), reduced food intake, or increased activity. If A1c is low but you are having symptoms of low blood sugar, the pattern is a reason to review your medication plan and glucose monitoring strategy with your clinician.
Some “low” findings are not about diabetes control at all. For example, unusually low creatinine can reflect lower muscle mass, which can matter if you are losing weight quickly and worried about muscle loss. The key is to interpret low values as part of the overall pattern rather than as a standalone win.
When results look on track
An “on track” pattern usually means your A1c and fasting glucose are aligned with your goals, fasting insulin (or an insulin-resistance estimate) is improving or stable, and your kidney and liver markers are reassuring. You may also see lipids moving in a favorable direction—often lower triglycerides and improved HDL cholesterol—especially when nutrition quality and activity are improving.
If you are on GLP-1 therapy, an optimal pattern is not only about glucose. It also includes stable kidney function (eGFR and creatinine), no concerning rise in liver enzymes, and lipids that support lower cardiovascular risk. Even when numbers are “in range,” trending over time is valuable: steady improvement across several markers is often more meaningful than a single perfect result.
When results trend high
A “high” pattern can show up in different ways. If A1c is high and fasting glucose is high, it usually suggests persistent hyperglycemia and a need to reassess your plan (nutrition, activity, sleep, stress, and medications). If A1c is high but fasting glucose is not, it can point to post-meal spikes, overnight glucose patterns, or an A1c that is being influenced by factors unrelated to glucose. Pairing A1c with fasting glucose and insulin helps narrow the possibilities.
High fasting insulin (especially with borderline or high glucose) often fits insulin resistance. High triglycerides, low HDL, and elevated inflammation markers can cluster with insulin resistance and raise cardiovascular risk. Kidney-related highs—such as elevated urine albumin-to-creatinine ratio—can appear early, sometimes before you notice symptoms, and deserve prompt clinician follow-up even if your glucose numbers are improving.
Factors that influence your panel results
Several real-world factors can shift multiple results at once. Recent illness, poor sleep, pain, and psychological stress can raise glucose and sometimes triglycerides. Rapid weight loss can improve glucose and triglycerides while also changing creatinine (through muscle mass changes) and liver enzymes (as the liver adapts). Medications matter: GLP-1 therapies often improve A1c and weight, but your overall pattern depends on dose, adherence, and what you eat; steroids can raise glucose; statins can change lipid patterns; SGLT2 inhibitors can affect kidney-related markers and hydration status.
Timing and preparation also matter. A true fasting sample (typically 8–12 hours, water allowed) makes fasting glucose and insulin more interpretable. Dehydration can concentrate some labs and make kidney markers look worse than they are. Finally, A1c can be influenced by anemia, hemoglobin variants, and conditions that change red blood cell lifespan, which is one reason this panel includes multiple ways to look at glycemia.
What’s included in this panel
- Glucose
- Urea Nitrogen (Bun)
- Creatinine
- Egfr
- Bun/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide
- Calcium
- Protein, Total
- Albumin
- Globulin
- Albumin/Globulin Ratio
- Bilirubin, Total
- Alkaline Phosphatase
- Ast
- Alt
- Creatinine, Random Urine
- Albumin, Urine
- Albumin/Creatinine Ratio, Random Urine
- Hemoglobin A1C
- Cholesterol, Total
- Hdl Cholesterol
- Triglycerides
- Ldl-Cholesterol
- Chol/Hdlc Ratio
- Ldl/Hdl Ratio
- Non Hdl Cholesterol
Frequently Asked Questions
Do I need to fast for this panel?
Fasting is usually recommended because fasting glucose and fasting insulin are much easier to interpret when you have not eaten for about 8–12 hours (water is typically fine). If your panel includes a lipid panel, fasting can also reduce day-to-day variability in triglycerides. Follow the instructions provided with your order, and ask your clinician how to handle diabetes medications the morning of the draw—especially insulin or medications that can cause low blood sugar.
How often should you repeat a diabetes monitoring panel?
A common cadence is every 3 months when you are newly diagnosed, changing medications, or actively working on lowering A1c, because A1c reflects roughly the prior 2–3 months. If you are stable and at goal, your clinician may space testing out (often every 6–12 months) while still checking kidney and lipid markers at appropriate intervals. The best schedule depends on your baseline risk, medication changes, and whether you are trending in the right direction.
Why can my A1c and my fingerstick or CGM glucose look like they disagree?
A1c is an average measure of glucose exposure over time, while fingerstick or CGM readings are snapshots (or short-term trends). You can have a normal fasting glucose but frequent post-meal spikes that raise A1c. You can also have an A1c that is affected by non-glucose factors such as anemia, recent blood loss, or conditions that change red blood cell lifespan. This panel helps by pairing A1c with fasting glucose and insulin, and by adding organ and risk markers that provide context.
What does fasting insulin add if I already have glucose and A1c?
Fasting insulin can help you understand whether your body is needing to produce (or you are needing to take) a lot of insulin to keep glucose controlled. Higher insulin alongside normal or mildly elevated glucose often fits insulin resistance. Over time, improving insulin levels can be a sign that lifestyle changes or medications are improving metabolic health, even before A1c fully reflects it.
Why are kidney tests and a urine albumin-to-creatinine ratio included?
Diabetes can affect the kidneys early, sometimes before symptoms appear. Blood markers like creatinine and eGFR estimate filtration, while urine albumin-to-creatinine ratio (uACR) looks for albumin “leakage,” which can be an early sign of kidney stress and a cardiovascular risk marker. Finding changes early gives you and your clinician more options to protect kidney health.
Is this panel useful if I’m taking a GLP-1 medication?
Yes. GLP-1 therapies can improve A1c and weight, but you still want to monitor the broader picture: fasting glucose trends, lipid changes, and kidney and liver markers. If you are losing weight quickly, this panel can also help you spot patterns that might prompt a conversation about nutrition adequacy, resistance training, and medication dosing.
Should I order this panel or order individual tests separately?
A panel is most helpful when you want a coordinated snapshot that is easier to trend over time and interpret as a pattern. Ordering individual tests can make sense if you and your clinician are focusing on a single question (for example, a focused glucose-insulin check). If your main goal is to understand overall control plus cardiometabolic and organ-health context, a bundled panel is usually more efficient.